Hankil Yoon - 16 May 2025 Form 4 Insider Report for Apimeds Pharmaceuticals US, Inc. (APUS)

Role
Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Issuer symbol
APUS
Transactions as of
16 May 2025
Net transactions value
$0
Form type
4
Filing time
20 May 2025, 17:11:26 UTC
Previous filing
08 May 2025
Next filing
17 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yoon Hankil Director 2 EAST BROAD STREET, 2ND FLOOR, HOPEWELL /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact 20 May 2025 0002041300

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APUS Stock Option (right to buy) Award $0 +5,780 $0.000000 5,780 16 May 2025 Common Stock, par value $0.01 per share 5,780 $1.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in full and become exercisable on 05/16/2026.